Neuroendocrine Carcinoma of Prostate

Neuroendocrine carcinoma of the prostate is a rare and aggressive form of prostate cancer that develops when prostate cells change their behavior and stop responding to hormone-based treatments that normally control prostate cancer growth.

Table of contents

• What is Neuroendocrine Carcinoma of Prostate?
• Associated Anatomy
• How Common is This Cancer?
• How This Cancer Develops
• Clinical Features and Biological Changes
• Diagnosis
• Treatment Approaches
• Prognosis and Outlook

What is Neuroendocrine Carcinoma of Prostate?

Neuroendocrine carcinoma of the prostate is a rare type of prostate cancer that differs significantly from the common form of prostate cancer called adenocarcinoma (a cancer that begins in glandular cells). This cancer is particularly aggressive and often requires different treatment approaches than typical prostate cancer^[1].

The disease can arise in two ways. It may develop “de novo,” meaning it appears from the beginning without a previous history of typical prostate cancer. More commonly, it develops in later stages of prostate cancer as a mechanism of treatment resistance, particularly in patients who have been treated with hormone-blocking medications^[3][6].

Associated Anatomy

• Prostate gland

The prostate is a small gland about the size of a walnut that sits between the bladder and the penis, just in front of the rectum. The tube through which urine passes, called the urethra, runs through the prostate. The prostate produces seminal fluid that helps to feed and protect sperm. During ejaculation, the prostate secretes this fluid into the urethra, where it mixes with sperm and is expelled through the penis as semen^[3].

Approximately 1% of all the cells within a normal prostate gland are neuroendocrine in origin. These specialized cells were first described in 1944 and are part of a larger system of hormone-producing cells throughout the body. In a healthy prostate, these cells are thought to be involved in prostate growth, development, and regulation of secretion processes^[4].

How Common is This Cancer?

Neuroendocrine carcinoma of the prostate is rare, accounting for less than 0.5% to 2% of all prostate cancers^[3][6]. The condition is more commonly referred to as neuroendocrine prostate cancer or NEPC.

However, the incidence of this type of cancer appears to be rising, particularly in men with advanced prostate cancer who have been treated with newer, more potent hormone-blocking drugs. Studies suggest that neuroendocrine features may be found in up to 15-20% of patients with castration-resistant prostate cancer (prostate cancer that continues to grow despite hormone treatment) after treatment with powerful drugs that target male hormones^[7].

How This Cancer Develops

Understanding how neuroendocrine carcinoma of the prostate develops helps explain why it behaves differently from typical prostate cancer. Normal prostate cancer depends heavily on male hormones (called androgens) to grow. Treatments that block these hormones, known as androgen deprivation therapy, are the standard approach for prostate cancer^[1].

Most prostate cancers initially respond well to hormone-blocking treatments. However, some cancer cells eventually find ways to survive and grow without depending on male hormones. One way they do this is through a process called lineage plasticity, where the cancer cells essentially change their identity. They transform from typical prostate cancer cells into neuroendocrine cancer cells^[1][7].

This transformation process is complex. When neuroendocrine prostate cancer develops from existing prostate cancer during treatment, it arises from the same original cancer cells but acquires new characteristics that allow it to survive without male hormones. The cancer retains some of its original genetic changes while acquiring new molecular features that drive its growth in a hormone-independent way^[7].

Clinical Features and Biological Changes

Neuroendocrine carcinoma of the prostate has several distinct characteristics that set it apart from typical prostate cancer. One of the most important features is that it becomes independent of the androgen receptor (AR), a protein that normally drives prostate cancer growth. As tumors progress from prostate adenocarcinoma to neuroendocrine carcinoma, they typically show reduced levels of the androgen receptor, PSA (prostate-specific antigen, a protein commonly used to monitor prostate cancer), and PSMA (prostate-specific membrane antigen)^[1].

At the genetic level, research has identified several key changes that facilitate this transformation. Loss of two important tumor-suppressing genes, called RB1 and TP53, appears to be particularly important in allowing the lineage plasticity that leads to neuroendocrine cancer. Additionally, significant changes in how genes are regulated (called epigenetic changes) further drive tumor growth and the expression of neuronal and neuroendocrine characteristics^[1].

These molecular insights have provided a framework for understanding this aggressive cancer subtype and have begun to suggest new approaches for treatment based on specific biological markers^[1].

Diagnosis

Diagnosing neuroendocrine carcinoma of the prostate can be challenging. It can be difficult to accurately distinguish from typical prostate cancer without expert review of cells under a microscope. Because approximately 1% of cells in a normal prostate are neuroendocrine in origin, it is not unusual to see some neuroendocrine cells in a prostate cancer sample^[3].

What is vital is establishing not only whether neuroendocrine cells are present and abnormal (meaning cancerous), but also how many there are compared to typical prostate cancer cells. This requires careful examination by a pathologist with expertise in this area^[3].

When a patient presents with symptoms, the clinical picture may be quite different from typical prostate cancer. Patients may present with rapidly progressive disease, including widespread metastases (cancer spread to other parts of the body), often to bones and organs. Some patients may have symptoms such as fever, weight loss, breathing difficulties, and severe back pain from spinal involvement^[6].

An important diagnostic clue is that PSA levels may be low or not elevated, even when the cancer is widespread. This is because neuroendocrine prostate cancer cells often do not produce much PSA, unlike typical prostate cancer cells^[1].

Treatment Approaches

Treatment of neuroendocrine carcinoma of the prostate is particularly challenging. Because this cancer does not depend on male hormones for growth, standard hormone-blocking treatments that work well for typical prostate cancer are not effective^[1].

The standard first-line treatment approach is typically platinum-based chemotherapy, similar to what is used for small cell lung cancer, another type of neuroendocrine cancer. This usually involves a combination of platinum drugs (such as cisplatin) with another chemotherapy drug called etoposide^[10].

While this chemotherapy approach can be effective initially, the response typically does not last long. Treatment outcomes for second-line therapy, when the first treatment stops working, have been particularly unfavorable, with progression-free survival often being 3 months or shorter. Other chemotherapy drugs such as docetaxel, amrubicin, and irinotecan have been used as second-line treatments, but their effectiveness has been modest with response durations typically less than 6 months^[10].

Newer treatment approaches are being actively investigated in clinical trials. Some patients with specific genetic alterations affecting DNA repair mechanisms may benefit from drugs called PARP inhibitors. Other studies are exploring immune checkpoint inhibitors and molecularly targeted agents^[10][7].

Recent reports have also described the use of specialized radiation therapy approaches, such as stereotactic ablative radiotherapy, in selected patients, with some achieving long-term survival^[9].

Prognosis and Outlook

Neuroendocrine carcinoma of the prostate generally has a poor prognosis. The aggressive nature of this cancer is attributed in part to late diagnosis and a lack of highly effective therapeutic agents^[1].

The cancer is characterized by an aggressive clinical course. Locally advanced or metastatic disease is common at the time of presentation. The disease shares many clinical features with small cell carcinoma of the lung, which is also known for its aggressive behavior^[6].

However, there are reasons for hope. Research into the biological mechanisms underlying this disease has accelerated in recent years. As scientists better understand the dynamic process that leads to neuroendocrine prostate cancer, new strategies for earlier detection and intervention are being developed^[1][7].

The development of biomarker-driven therapeutic strategies—treatments selected based on specific molecular features of a patient’s tumor—may ultimately improve outcomes. Clinical trials focused on targeting the lineage plasticity process itself or specific vulnerabilities in neuroendocrine prostate cancer are ongoing and may lead to better treatment options in the future^[7].